Novo Nordisk A/S (NYSE:NVO) Shares Sold by Hexagon Capital Partners LLC

Hexagon Capital Partners LLC decreased its position in Novo Nordisk A/S (NYSE:NVO) by 11.1% in the first quarter, HoldingsChannel.com reports. The fund owned 5,865 shares of the company’s stock after selling 729 shares during the period. Hexagon Capital Partners LLC’s holdings in Novo Nordisk A/S were worth $407,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Strategic Investment Solutions Inc. IL raised its stake in shares of Novo Nordisk A/S by 2,727.3% in the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock worth $27,000 after purchasing an additional 300 shares during the last quarter. Copeland Capital Management LLC increased its holdings in Novo Nordisk A/S by 184.8% in the 1st quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock worth $27,000 after buying an additional 255 shares during the period. North Capital Inc. purchased a new position in Novo Nordisk A/S during the 1st quarter worth approximately $27,000. Park Square Financial Group LLC acquired a new stake in Novo Nordisk A/S during the 4th quarter valued at approximately $29,000. Finally, Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $33,000. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently issued reports on the stock. Kepler Capital Markets raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. BNP Paribas began coverage on Novo Nordisk A/S in a research note on Tuesday, April 15th. They set an “underperform” rating for the company. Hsbc Global Res raised Novo Nordisk A/S to a “strong-buy” rating in a report on Monday, April 28th. Guggenheim lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Thursday, April 17th. Finally, Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a report on Friday, April 25th. Two analysts have rated the stock with a sell rating, five have issued a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $112.00.

Novo Nordisk A/S Trading Down 1.1%

NVO stock opened at $69.05 on Friday. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $143.69. The company has a quick ratio of 0.56, a current ratio of 0.74 and a debt-to-equity ratio of 0.70. The firm has a market cap of $308.31 billion, a P/E ratio of 20.43, a PEG ratio of 1.35 and a beta of 0.64. The company’s 50-day simple moving average is $69.96 and its 200-day simple moving average is $75.71.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a return on equity of 80.94% and a net margin of 34.52%. The company had revenue of $11.87 billion during the quarter. As a group, equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.